

P910 DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Jahanzaib Khwaja^{*1}, Oliver Cohen², Kim Summers³, Shameem Mahmood^{2,1}, Helen Lachmann², Julian Gillmore², Carol Whelan², Orlando Agrippa³, Ashutosh Wechalekar^{2,1}

¹Haematology, University College London Hospitals, United Kingdom; ²National Amyloidosis Centre, University College London (Royal Free Campus), London, United Kingdom; ³Sanius Health

Background:

Survival in systemic AL amyloidosis depends on the severity of organ involvement and haematological response to treatment. Since cardiac involvement is the major determinant of mortality, accurate staging is critical. Two validated staging systems, Mayo 2012 (stage I-IV) and European modification of Mayo 2004 (stage I-IIIb), stratify patients according to different thresholds of surrogate markers (NT-proBNP, troponin T and, for Mayo 2012, serum free light chains). However patients included in these original models were not treated with a uniform induction protocol. We report survival outcomes and impact on 6-minute walk time (6MWT) in a large cohort of uniformly treated AL amyloidosis patients stratified by both staging systems.

Aims:

We aimed to evaluate the prognostic stratification by Mayo 2012 and European staging systems in a cohort of patients treated with bortezomib-based regimens upfront and to analyse 6MWT at baseline, six and twelve months.

Methods:

Patients enrolled in a prospective observational study at the UK National Amyloidosis Centre from 2012–2017 were analysed. Patients underwent comprehensive assessments including NT-proBNP, troponin, serum free light chain and 6MWT measurement at diagnosis, 6 months and annually thereafter. Overall survival (OS) estimates were compared using Cox regression and the log-rank test.

Results:

799 patients (465 male, 334 female) with a median age of 66 years (IQR 58-72) were included. The median OS was 74 months (95% CI 68-79). There was no significant difference in OS for Mayo 2012 stage III vs IV patients (median 27 vs 20 months, $p=0.18$) but was a difference in stage IIIa vs IIIb (32 vs 7 months, $p<0.0001$). Median baseline 6-minute walk distance was 362m (IQR 230-460) and significantly decreased with worsening cardiac stage across both staging systems at all time points ($p<0.0001$). After 6 months, median 6MWT had decreased by a median of 28m across all Mayo stages and all haematological responses (CR, VGPR, PR, NR). After 12 months, 6MWT improved most significantly by median 8m and 81m in Mayo IV and European modified IIIb patients in CR but not for any other haematologic response category ($<VGPR$). However, using the European modification cardiac stage, there was no improvement in for patients with stage IIIa disease (median -1m) whilst there was marked improvement (median 52m) for stage IIIb patients at 12 months over baseline.

On multivariable analysis, an improvement by $>44m$ from baseline at 6 months (Mayo: HR 0.58 $p=0.033$; European: HR 0.57, $p=0.0435$) or 12 months (Mayo: HR 0.58 95% $p=0.018$; European: HR 0.6253, $p=0.0467$) was an independent predictor of better outcomes in a model that included haematological responses and (separately) Mayo 2012/European modified staging systems independently.

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

